利用针对新生血管性眼病优化的双特异性CrossMAb靶向关键血管生成途径。
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
作者信息
Regula Jörg T, Lundh von Leithner Peter, Foxton Richard, Barathi Veluchamy A, Chui Ming Gemmy Cheung, Tun Sai Bo Bo, Wey Yeo Sia, Iwata Daiju, Dostalek Miroslav, Moelleken Jörg, Stubenrauch Kay G, Nogoceke Everson, Widmer Gabriella, Strassburger Pamela, Koss Michael J, Klein Christian, Shima David T, Hartmann Guido
出版信息
EMBO Mol Med. 2019 May;11(5). doi: 10.15252/emmm.201910666.
Abstract
[Image: see text]
摘要
[图像：见正文]
相似文献
1
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.利用针对新生血管性眼病优化的双特异性CrossMAb靶向关键血管生成途径。
EMBO Mol Med. 2019 May;11(5). doi: 10.15252/emmm.201910666.
2
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.利用针对新生血管性眼病优化的双特异性CrossMAb靶向关键血管生成途径。
EMBO Mol Med. 2017 Jul;9(7):985. doi: 10.15252/emmm.201707895.
3
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.利用针对新生血管性眼病优化的双特异性交叉单克隆抗体靶向关键血管生成途径。
EMBO Mol Med. 2016 Nov 2;8(11):1265-1288. doi: 10.15252/emmm.201505889. Print 2016 Nov.
4
Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.双特异性抗体联合化疗靶向 VEGFA 和 Ang-2 治疗化疗耐药结直肠癌的疗效。
Molecules. 2019 Aug 7;24(16):2865. doi: 10.3390/molecules24162865.
5
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins.历经十年：CrossMab 技术在治疗性双特异性抗体和抗体融合蛋白开发中的应用。
MAbs. 2021 Jan-Dec;13(1):1967714. doi: 10.1080/19420862.2021.1967714.
6
The use of CrossMAb technology for the generation of bi- and multispecific antibodies.利用CrossMAb技术生成双特异性和多特异性抗体。
MAbs. 2016 Aug-Sep;8(6):1010-20. doi: 10.1080/19420862.2016.1197457. Epub 2016 Jun 10.
7
Engineering therapeutic bispecific antibodies using CrossMab technology.利用 CrossMab 技术工程治疗性双特异性抗体。
Methods. 2019 Feb 1;154:21-31. doi: 10.1016/j.ymeth.2018.11.008. Epub 2018 Nov 16.
8
Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.血管生成素-2（Ang-2）-血管内皮生长因子-A（VEGF-A）双特异性单克隆抗体（CrossMab），一种新型的同时阻断 VEGF-A 和 Ang-2 功能的人源 IgG1 抗体，具有强大的抗肿瘤、抗血管生成和抗转移疗效。
Clin Cancer Res. 2013 Dec 15;19(24):6730-40. doi: 10.1158/1078-0432.CCR-13-0081. Epub 2013 Oct 4.
9
Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.通过CD20-243双特异性抗体同时靶向CD20和HLA-DR来对抗非霍奇金淋巴瘤。
MAbs. 2014 May-Jun;6(3):740-8. doi: 10.4161/mabs.28613. Epub 2014 Mar 26.
10
Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma.血管生成素-2-血管内皮生长因子-A双特异性抗体在肾细胞癌中的作用
Cancer Invest. 2015;33(8):378-86. doi: 10.3109/07357907.2015.1047505. Epub 2015 Jun 26.
引用本文的文献
1
Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials.在YOSEMITE/RHINE试验中，法西单抗与阿柏西普对糖尿病性黄斑水肿患者高反射灶的影响。
Ophthalmol Sci. 2025 Apr 19;5(5):100798. doi: 10.1016/j.xops.2025.100798. eCollection 2025 Sep-Oct.
2
The HAT Inhibitor ISOX-DUAL Diminishes Ischemic Areas in a Mouse Model of Oxygen-Induced Retinopathy.组蛋白乙酰转移酶抑制剂ISOX-DUAL可减少氧诱导性视网膜病变小鼠模型中的缺血区域。
Genes Cells. 2025 Mar;30(2):e13196. doi: 10.1111/gtc.13196.
3
Sterile Intraocular Inflammation Associated With Faricimab.与法西单抗相关的无菌性眼内炎症。
JAMA Ophthalmol. 2024 Oct 10;142(11):1028-36. doi: 10.1001/jamaophthalmol.2024.3828.
4
Integrated Assessment of OCT, Multimodal Imaging, and Cytokine Markers for Predicting Treatment Responses in Retinal Vein Occlusion Associated Macular Edema: A Comparative Review of Anti-VEGF and Steroid Therapies.用于预测视网膜静脉阻塞相关性黄斑水肿治疗反应的光学相干断层扫描、多模态成像和细胞因子标志物的综合评估：抗血管内皮生长因子和类固醇疗法的比较性综述
Diagnostics (Basel). 2024 Sep 7;14(17):1983. doi: 10.3390/diagnostics14171983.
5
Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications.抗血管内皮生长因子药物治疗新生血管性年龄相关性黄斑变性：从作用机制到临床应用的进展
Front Med (Lausanne). 2024 Jul 19;11:1411278. doi: 10.3389/fmed.2024.1411278. eCollection 2024.
6
In vivo monitoring of active subretinal fibrosis in mice using collagen hybridizing peptides.使用胶原杂交肽对小鼠视网膜下活性纤维化进行体内监测。
Lab Anim (NY). 2024 Aug;53(8):196-204. doi: 10.1038/s41684-024-01408-0. Epub 2024 Jul 26.
7
Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degeneration.玻璃体内法米替尼治疗难治性新生血管性年龄相关性黄斑变性的短期疗效。
Graefes Arch Clin Exp Ophthalmol. 2024 Sep;262(9):2867-2874. doi: 10.1007/s00417-024-06485-y. Epub 2024 Apr 12.
8
Old Problem in a New Guise: Retinal Pigment Epithelium Tear after Intravitreal Faricimab (Vabysmo) Injection.新瓶装旧酒：玻璃体内注射法西单抗（Vabysmo）后视网膜色素上皮撕裂
Case Rep Ophthalmol. 2023 May 26;14(1):241-244. doi: 10.1159/000529930. eCollection 2023 Jan-Dec.
9
Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion.在视网膜新生血管形成和缺血/再灌注模型中，描绘血管生成素-2抑制对血管通透性和炎症的影响。
Front Cell Neurosci. 2023 Jun 12;17:1192464. doi: 10.3389/fncel.2023.1192464. eCollection 2023.
10
Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy.重新思考药物递送系统在新生血管性年龄相关性黄斑变性治疗中的潜力和必要性。
Front Bioeng Biotechnol. 2023 May 23;11:1199922. doi: 10.3389/fbioe.2023.1199922. eCollection 2023.
本文引用的文献
1
Efficacy of simultaneous VEGF-A/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization.同时抑制 VEGF-A/ANG-2 对自发性脉络膜新生血管的抑制作用。
EMBO Mol Med. 2019 May;11(5). doi: 10.15252/emmm.201810204.
Zotero 插件